Table 1 Summary of included studies and patient characteristics

Lee et al. 2014

G1: 40 mg TCA/PI

25

50.3

2/13

7.6

4

N/A

−0.63 (0.70)

−0.02 (0.75)

G2: 40 mg TCA/UInar-O

24

52.6

0/14

9.4

4

N/A

−0.73 (0.55)

−0.35 (0.78)

G3: 40 mg TCA/UInar-I

26

55.2

1/14

8.9

4

N/A

−1.16 (0.62)

−0.38 (0.70)

Makhlouf et al. 2014

G1: 80 mg TCA/PI

40

52.2

8/32

unknown

2

19/40

NA

NA

G2: 80 mg TCA/Ulnar-I

37

45.7

2/35

unknown

2

34/37

NA

NA

Ustun et al. 2013

G1: 40 mg MTP/PI

23

42.7

1/22

10.2

6

N/A

−0.95 (0.63)

−1.16 (0.94)

G2: 40 mg MTP/Ulnar-O

23

46.0

4/19

16.8

6

N/A

−1.27 (0.61)

−1.15 (0.68)

Atroshi et al. 2013

G1: placebo

37

49

9/28

14% ≦ 12 months

5

N/A

−0.47 (0.60)

N/A

G2: 40 mg MTP/PI

37

44

10/27

27% ≦ 12 months

5

N/A

−1.33 (0.98)

N/A

Karadas et al. 2012

G1: placebo

30

48.4

2/17

9.9

8

N/A

−0.03 (0.52)

−0.03 (0.54)

G2: 40 mg TCA/PI

30

46.4

3/17

9.5

8

N/A

−0.30 (0.69)

−0.15 (0.92)

Peters et al. 2010

G1: placebo

31

57.6

7/26

13

1

5/31

−0.29 (0.55)

0.14 (0.56)

G2: 10 mg TCA/PI

35

56.5

9/27

26

1

17/35

−0.92 (0.71)

−0.58 (0.84)

Habib et al. 2006

G1: 35 mg of MTP/PI

21

43.3

4/17

5.5

6

15/21

N/A

N/A

G2: 12 mg of MTP/DI

21

41

5/16

6

6

14/21

N/A

N/A

Armstrong et al. 2004

G1: 6 mg BMT/PI

43

51.9

8/35

61% > 1 year

2

30/43

−0.78 (0.80)

−0.64 (0.87)

G2: placebo

38

51.2

10/28

66% > 1 year

2

13/38

−0.19 (0.62)

−0.13 (0.44)

O’Gradaigh et al. 2000

G1: 100 mg HC/PI

32

unknown

unknown

unknown

6

20/32

N/A

N/A

G2: placebo

20

unknown

unknown

unknown

6

1/20

N/A

N/A

Dammers et al. 1999

G1: 40 mg MTP/PI

30

53

6/24

32

4

23/30

N/A

N/A

G2: placebo

30

51

4/26

25

4

6/30

N/A

N/A